Reference

New antiinfectious biomaterials

New antiinfectious biomaterials. Ciprofloxacin containing polyurethanes as potential drug delivery systems to prevent foreign-body infections. Schierholz, Joerg M.; Rump, Alexis; Pulverer, Gerhard (B. Braun A.-G., Melsungen D-34212, Germany). Arzneimittel-Forschung, 47(1), 70-74 (English) 1997 Cantor. CODEN: ARZNAD. ISSN: 0004-4172. DOCUMENT TYPE: Journal CA Section: 63 (Pharmaceuticals) Section cross-reference(s): 1 Device related infections are an increasing problem since foreign materials are used in modern medicine. Ciprofloxacin-HCl salt (CAS 86393-32-0) and lipophilic ciprofloxacin-betaine (Bay o 9867) incorporated into polyurethanes by solvent casting technique were studied in order to develop antiinfectious properties of this biomaterial. Drug release rates, bacterial colonization and morphol. features of the polymer-ciprofloxacin combinations were studied and the physico-chem. mechanisms of the delivery were discussed. Ciprofloxacin salt showed a fast initial release rate, whereas ciprofloxacin-betaine was characterized by a more continuous release behavior. A higher diffusion of the lipophilic ciprofloxacin-betaine in the polymer could be shown as compared to its salt incorporated into the polyurethane. Bacterial colonization to the antibiotic-loaded polyurethanes was inhibited effectively only by prepns. showing a slower but more sustained drug release. SEM demonstrated that the polyurethane-antibiotic combination was most homogeneous for ciprofloxacin-betaine. Polyurethane material loaded with ciprofloxacin salt showed crystals at the surface and a granular structure of the polymeric matrix. Cryst. structure of the drug on polymeric surfaces varied with loading concn. and lipophilicity. High homogeneity is required for a sustained and prolonged release and effective inhibition of bacterial colonization.

Aqueous compositions containing ciprofloxacin

Aqueous compositions containing ciprofloxacin. Canovas Soler, Pedro; Delgadillo Duarte, Joaquin; Moreno Rueda, Juan (Bayvit, S.A.; Canovas Soler, Pedro; Delgadillo Duarte, Joaquin; Moreno Rueda, Juan, Spain). PCT Int. Appl. WO 9705880 A1 20 Feb 1997, 15 pp. DESIGNATED STATES: W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM; RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE. (Spanish). (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: A61K031-495. ICS: A61K009-08. APPLICATION: WO 1996-ES155 26 Jul 1996. PRIORITY: ES 1995-1578 3 Aug 1995. DOCUMENT TYPE: Patent CA Section: 63 (Pharmaceuticals) Aq. compns. for treatment of otitis media with perforation of the tympanic membrane contain the broad-spectrum antibiotic ciprofloxacin.HCl.H2O 0.12-0.6 (equiv. to 0.1-0.5% free base), buffer (pH 4-5) 0.5-3.0, nonionic surface-active agent 0.05-0.3, thickening agent 0.5-2.0 g, and H2O to 100 mL. This soln. is packaged in sterile single dosage units without preservatives. Thus, an aq. soln. was prepd. contg. ciprofloxacin. There are some commonly used reagents like 86393-32-0 in this article.HCl.H2O 0.40, AcOH 0.45, NaOAc.3H2O 1.20, polysorbate 80 0.19, methylcellulose 1.15, and glycerin 1.62 wt.%. .